Mode
Text Size
Log in / Sign up
Phase 4 Completed N=116 Randomized Double-blind Other

Does Deep Neuromuscular Blockade Improve Operating Conditions During Total Hip Replacements?

Arthropathy of Hip
Source: ClinicalTrials.gov NCT03219294 ↗
Enrolled (actual)
116
Serious AEs
0.0%
Results posted
Sep 2019
Primary outcomePrimary: Surgical Conditions — 1; 2; 11; 10 Participants
◆ Published Evidence
No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

During many surgeries, increased muscle tension makes it harder for the surgeon to expose the site of surgery and work within the incision. Neuromuscular blockade (NMB) drugs such as Vecuronium bind to neurotransmitter (acetyl choline) receptors at the neuromuscular junction, blocking their action and producing muscle relaxation. This muscle relaxation allows easier retraction of muscle tissues and manipulation of structures in the wound. Improved surgical conditions are likely to result in improved patient outcomes. While increased depths of NMB have been shown to optimize surgical conditions during intra-abdominal and retroperitoneal procedures, the impact of NMB depth has not been reported for orthopedic surgeries.1 To address this, we propose to study the effect of NMB depth on surgical conditions during total hip replacement (THR).

Outcome Measures

OutcomeResultp-value
PRIMARY
Surgical Conditions
1; 2; 11; 10; 30; 29
SECONDARY
Duration of Surgery
32.6; 33.8

Eligibility Criteria

Inclusion Criteria

  • American Society of Anesthesiologists (ASA) Physical status 1-3
  • age 50-75
  • English speaking
  • able to provide informed consent
  • BMI equal to less than 30
  • non-emergent THR by anterolateral minimally invasive non-cemented total hip arthroplasty

Exclusion Criteria

  • Revision surgery
  • Bilateral THR
  • ASA 4+
  • age less than 50 or greater than 75
  • BMI greater than 30
  • unable to provide informed consent
  • women taking oral contraceptives (Sugammadex used for reversal interferes with their efficacy
  • contraindications to general inhalation anesthesia (such as malignant hyperthermia)
  • contraindications to NMB (known allergy to NMB)
  • chronic kidney disease
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03219294). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search